ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts

Recurrent somatic mutations of the epigenetic modifier and tumor suppressor ASXL1 are common in myeloid malignancies, including chronic myeloid leukemia (CML), and are associated with poor clinical outcome. CRISPR/Cas9 has recently emerged as a powerful and versatile genome editing tool for genome e...

Descripción completa

Detalles Bibliográficos
Autores principales: Valletta, Simona, Dolatshad, Hamid, Bartenstein, Matthias, Yip, Bon Ham, Bello, Erica, Gordon, Shanisha, Yu, Yiting, Shaw, Jacqueline, Roy, Swagata, Scifo, Laura, Schuh, Anna, Pellagatti, Andrea, Fulga, Tudor A., Verma, Amit, Boultwood, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792541/
https://www.ncbi.nlm.nih.gov/pubmed/26623729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792541/
https://www.ncbi.nlm.nih.gov/pubmed/26623729

Ejemplares similares